Acorn Wealth Advisors LLC Acquires Shares of 2,349 Gilead Sciences, Inc. (NASDAQ:GILD)

Acorn Wealth Advisors LLC bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 2,349 shares of the biopharmaceutical company’s stock, valued at approximately $217,000.

Several other institutional investors and hedge funds have also modified their holdings of GILD. HHM Wealth Advisors LLC increased its position in Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares during the last quarter. YANKCOM Partnership bought a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $28,000. Decker Retirement Planning Inc. acquired a new position in Gilead Sciences in the fourth quarter worth approximately $29,000. Valued Wealth Advisors LLC raised its position in Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 161 shares in the last quarter. Finally, Crews Bank & Trust acquired a new stake in Gilead Sciences in the fourth quarter valued at approximately $31,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $111.51 on Wednesday. The business’s fifty day moving average is $96.17 and its two-hundred day moving average is $89.35. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The firm has a market cap of $138.97 billion, a P/E ratio of 301.39, a P/E/G ratio of 0.71 and a beta of 0.18. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $112.11.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be issued a dividend of $0.79 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 2.83%. Gilead Sciences’s dividend payout ratio is currently 854.05%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the stock. BMO Capital Markets raised their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a report on Wednesday, February 12th. Citigroup began coverage on Gilead Sciences in a research report on Thursday, November 14th. They issued a “buy” rating and a $125.00 price target for the company. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a “hold” rating to a “buy” rating and increased their price objective for the company from $80.00 to $120.00 in a report on Tuesday, February 18th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Finally, Piper Sandler lifted their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, February 12th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $102.08.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 8,500 shares of the company’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $91.96, for a total transaction of $781,660.00. Following the transaction, the chief financial officer now directly owns 132,373 shares in the company, valued at approximately $12,173,021.08. This represents a 6.03 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders have sold 542,001 shares of company stock worth $52,230,551. Insiders own 0.16% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.